ND0612 Reduces OFF Time for Motor Fluctuations in Parkinson Disease at 12 Months
Published: June 23rd 2024 | Updated: June 24th 2024An open-label phase 2b trial assessing ND0612 showed that the rate of treatment responders increased over a 12-month period among patients with Parkinson disease who experienced motor fluctuation.
A Time to Recognize and Enhance Understanding of Migraine Disorders: Jessica Ailani, MD
June 21st 2024The director of the MedStar Georgetown Headache Center talked about recognizing the struggles of patients with migraine disorders and the importance of bringing awareness of available treatments to this patient population. [WATCH TIME: 5 minutes]
Understanding the Importance of Maternal-Fetal Circadian Synchrony
June 20th 2024Eric Herzog, PhD, a chronobiologist and professor of biology and neuroscience at Washington University, provided thoughts on a number of topics related to sleep during pregnancy and the significance of maintaining circadian rhythms.
New HEALEY-ALS Trial Results Show CNM-Au8’s Effect on Survival, Neurofilament Light
June 19th 2024CNM-Au8, an oral suspension of clean-surfaced, catalytically-active gold nanocrystals, resulted in prolonged survival and reductions in neurofilament light, a prominent biomarker of neuroaxonal damage.
NeuroVoices: Alessio Travaglia, PhD, on New FNIH Partnership to Accelerate ALS Biomarkers, Research
June 19th 2024The director at the Foundation for the National Institutes of Health provided commentary on a recently launched partnership aimed at building a repository of ALS data to advance drug development for the disease.
Nocturnal Hypoxia and Sleep Apnea Associated With Late-Onset Epilepsy
Published: June 18th 2024 | Updated: June 19th 2024A recent study showed a significant association between sleep apnea, additional sleep characteristics, and late-onset epilepsy in older adults, even after adjusting for comorbidities.
Mixed Topline Data Reported in Phase 3 RAISE Trial of Ganaxolone for Refractory Status Epilepticus
June 18th 2024Marinus Pharmaceuticals reported that it will continue to analyze the full dataset and engage with the FDA to discuss the future of ganaxolone for treating refractory status epilepticus.
Phase 1/2 Studies Highlight Durable Impacts of Gene Therapy TSHA-102 in Rett Syndrome
June 18th 2024Initial data from a few pediatric and adult patients with Rett syndrome showed that treatment with TSHA-102 resulted in numerous positive enhancements across multiple efficacy measures and clinical domains.
Depression Linked With Worsened Non-Motor Symptoms in Parkinson Disease
June 18th 2024Patients with Parkinson disease and depression exhibit significantly worse nonmotor symptoms, highlighting the need for comprehensive management including orthostatic hypotension, constipation, and hyposexuality.
A Personalized Approach to Treating Gait Issues in Multiple Sclerosis: the Cionic Neural Sleeve
June 17th 2024Douglas A. Wadja, PhD, an assistant professor of neurology at Cleveland State University, detailed a study assessing an electrical nerve stimulation approach to alleviate gait dysfunction in patients with MS.
The Broader Impact of Eptinezumab for Chronic Migraine Management: Fawad Khan, MD, FACNS, FAHS
Published: June 17th 2024 | Updated: June 19th 2024The director of The McCasland Family Comprehensive Headache Center talked about findings from a study that explored the effect of eptinezumab treatment in a broader chronic migraine population. [WATCH TIME: 6 minutes]